187 related articles for article (PubMed ID: 19480095)
1. Kaletra oral solution: modification of confusing label: packaging. an infant died in France.
Prescrire Int; 2008 Aug; 17(96):140. PubMed ID: 19480095
[TBL] [Abstract][Full Text] [Related]
2. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
[No Abstract] [Full Text] [Related]
3. Improved tolerability and quality of life with the new lopinavir/ritonavir tablet formulation.
Olmo M; Ferrer E; Curto J; Barragán P; Saumoy M; Perulero N; Podzamczer D
J Infect; 2008 Dec; 57(6):503-5. PubMed ID: 18952298
[No Abstract] [Full Text] [Related]
4. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
[TBL] [Abstract][Full Text] [Related]
5. Rotarix packaging: labelling and packaging change. More improvement needed. Confusing oral syringe still available.
Prescrire Int; 2008 Oct; 17(97):196. PubMed ID: 19537308
[No Abstract] [Full Text] [Related]
6. Drug interactions. Kaletra and ezetimibe.
TreatmentUpdate; 2006; 18(3):8. PubMed ID: 17209242
[No Abstract] [Full Text] [Related]
7. Lopinavir + ritonavir oral solution: dangerous form for newborns.
Prescrire Int; 2011 Oct; 20(120):237. PubMed ID: 21970085
[No Abstract] [Full Text] [Related]
8. Ritonavir and lopinavir/ritonavir package inserts are updated.
AIDS Alert; 2005 Dec; 20(12):143-4. PubMed ID: 16397944
[No Abstract] [Full Text] [Related]
9. Changes in Kaletra labelling.
AIDS Patient Care STDS; 2004 Mar; 18(3):181-2. PubMed ID: 15116435
[No Abstract] [Full Text] [Related]
10. FDA notifications. Lopinavir/ritonavir label updated.
AIDS Alert; 2008 Aug; 23(8):92. PubMed ID: 18727173
[No Abstract] [Full Text] [Related]
11. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
[No Abstract] [Full Text] [Related]
12. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
13. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
[TBL] [Abstract][Full Text] [Related]
14. Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.
Chaubey SK; Sinha AK; Phillips E; Russell DB; Falhammar H
Sex Health; 2009 Sep; 6(3):254-7. PubMed ID: 19653965
[TBL] [Abstract][Full Text] [Related]
15. Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra).
Lin HC; Lu PL; Chang CH
Eye (Lond); 2007 Dec; 21(12):1540-1. PubMed ID: 17962822
[No Abstract] [Full Text] [Related]
16. Kaneuron: an oral solution of phenobarbital with dangerous packaging.
Prescrire Int; 2015 Apr; 24(159):95. PubMed ID: 25941699
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM
AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
[TBL] [Abstract][Full Text] [Related]
20. Medication errors.
Rheinstein PH; McGinnis TJ
Am Fam Physician; 1992 Jun; 45(6):2720-2. PubMed ID: 1595519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
